Fapon Biopharma, a biotech company focused on developing therapeutic antibodies and fusion proteins, has successfully enrolled the first patient in the Phase I clinical trial of FP008 in China. This groundbreaking immunotherapy for solid tumors is being evaluated for its safety and tolerability in patients with advanced solid tumors at Zhejiang Cancer Hospital. The patient has completed the Dose Limiting Toxicity (DLT) observation period with a positive safety profile, marking a significant milestone in the development of FP008.
FP008 is a next-generation immuno-oncology (IO) approach that combines anti-PD-1 × IL-10M fusion protein to address the limitations of current PD-1 inhibitors. By utilizing a proprietary IL-10 mutant, FP008 aims to eliminate the toxicity associated with the wild-type protein and provide a new therapeutic option for patients who are refractory to existing anti-PD-1/PD-L1 therapies. Preclinical studies have shown promising results, including enhanced infiltration of CD8⁺ T-cells into tumors, reduced exhaustion differentiation of CD8⁺ T-cells, and increased secretion of key cytokines in terminally exhausted CD8⁺ T-cells.
Furthermore, FP008 has demonstrated favorable safety and pharmacokinetic profiles in animal studies, leading to Investigational New Drug (IND) approvals from regulatory agencies in the U.S. and China. The multi-center Phase I trial, led by Zhejiang Cancer Hospital, aims to evaluate the safety and efficacy of FP008 in solid tumor patients resistant to anti-PD-1 antibodies. Professor Zhengbo Song, the Principal Investigator at Zhejiang Cancer Hospital, believes that FP008 offers a promising therapeutic strategy with a unique mechanism that could address unmet clinical needs in immuno-oncology.
FP008’s novel MOA and therapeutic potential make it a promising candidate for anti-PD-1 naïve or resistant patients. Fapon Biopharma is actively seeking strategic partnerships with biopharmaceutical companies to further develop and commercialize FP008. With a focus on innovation and cutting-edge technologies, Fapon Biopharma aims to deliver safer, more efficacious, and accessible biologics for patients with cancer, autoimmune diseases, and other unmet medical needs.
Key Takeaways:
– Fapon Biopharma has initiated a Phase I clinical trial for FP008, a novel immunotherapy for solid tumors, with the enrollment of the first patient in China.
– FP008 combines anti-PD-1 × IL-10M fusion protein to overcome the limitations of current PD-1 inhibitors and offer a new therapeutic option for patients resistant to existing therapies.
– Preclinical studies have shown promising results, including enhanced infiltration of CD8⁺ T-cells into tumors and increased secretion of key cytokines in terminally exhausted CD8⁺ T-cells.
– Fapon Biopharma is seeking strategic partnerships with biopharmaceutical companies to advance the development and commercialization of FP008.
Read more on finance.yahoo.com